Emmaus Life Sciences, Inc. (EMMA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 4M 8M 12M Q3 '21: 5.8M Q4 '21: 3M Q1 '22: 3.2M Q2 '22: 4.3M Q3 '22: 4.9M Q4 '22: 5.9M Q1 '23: 6.8M Q2 '23: 10.8M Q3 '23: 5M Q4 '23: 7.1M Q1 '24: 2.5M Q2 '24: 5.4M Q3 '24: 5.5M Q4 '24: 3.3M Q1 '25: 2.4M Q2 '25: 2.8M Q3 '25: 3.4M Q4 '25: 3.9M Q1 '26: 2M Q2 '26: 6.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 3.5M 7M 10.5M Q3 '21: 5.3M Q4 '21: 1M Q1 '22: 2.2M Q2 '22: 3.9M Q3 '22: 4.4M Q4 '22: 5.3M Q1 '23: 6.3M Q2 '23: 10.3M Q3 '23: 4.8M Q4 '23: 6.9M Q1 '24: 2.2M Q2 '24: 5.1M Q3 '24: 5.1M Q4 '24: 3M Q1 '25: 2.2M Q2 '25: 2.7M Q3 '25: 3.1M Q4 '25: 3.6M Q1 '26: 1.8M Q2 '26: 6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-6M -4M -2M 0 2M 4M 6M Q3 '21: -31K Q4 '21: -5M Q1 '22: -3.1M Q2 '22: -1.4M Q3 '22: -660K Q4 '22: -1.4M Q1 '23: -1.2M Q2 '23: 3.3M Q3 '23: 24K Q4 '23: 1.4M Q1 '24: -2.7M Q2 '24: 582K Q3 '24: 821K Q4 '24: -557K Q1 '25: -980K Q2 '25: -370K Q3 '25: 695K Q4 '25: 886K Q1 '26: -823K Q2 '26: 3.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-10.5M -7M -3.5M 0 3.5M 7M 10.5M Q3 '21: -3.2M Q4 '21: -6.9M Q1 '22: -1.5M Q2 '22: -8.9M Q3 '22: -391K Q4 '22: 200K Q1 '23: -3.5M Q2 '23: -1.6M Q3 '23: 67K Q4 '23: 1.2M Q1 '24: -4.3M Q2 '24: -2.2M Q3 '24: 1.8M Q4 '24: -1.7M Q1 '25: -2.3M Q2 '25: -1.1M Q3 '25: -2.1M Q4 '25: -2M Q1 '26: -3.3M Q2 '26: 1.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 700K 1.4M 2.1M Q3 '21: 445K Q4 '21: 2M Q1 '22: 1M Q2 '22: 396K Q3 '22: 540K Q4 '22: 645K Q1 '23: 429K Q2 '23: 508K Q3 '23: 214K Q4 '23: 191K Q1 '24: 257K Q2 '24: 241K Q3 '24: 394K Q4 '24: 309K Q1 '25: 225K Q2 '25: 150K Q3 '25: 247K Q4 '25: 235K Q1 '26: 168K Q2 '26: 344K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-6M -4M -2M 0 2M 4M 6M Q2 '21: 242K Q3 '21: 1.6M Q4 '21: 865K Q1 '22: -4.7M Q2 '22: -1.1M Q3 '22: -954K Q4 '22: 1.7M Q1 '23: -1.3M Q2 '23: -1.3M Q3 '23: 58K Q4 '23: 1M Q1 '24: 140K Q2 '24: -2.9M Q3 '24: 148K Q4 '24: 343K Q1 '25: 279K Q2 '25: -2.9M Q3 '25: 409K Q1 '26: -344K Q2 '26: 1.7M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Free Cash Flow Quarterly

-6M -4M -2M 0 2M 4M 6M Q4 '19: -391K Q1 '20: 1.8M Q2 '20: -3.5M Q3 '20: -2.6M Q4 '20: 1.9M Q3 '21: 1.6M Q4 '21: 803K Q1 '22: -4.7M Q2 '22: -1.1M Q3 '22: -954K Q4 '22: 1.7M Q1 '23: -1.3M Q2 '23: -1.3M Q3 '23: 58K Q4 '23: 1M Q1 '24: 136K Q2 '24: -2.9M Q3 '24: 147K Q4 '24: 337K Q3 '25: 409K Q1 '20 Q4 '20 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q3 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '20: 48.6M Q2 '20: 49M Q3 '20: 49M Q1 '21: 49.1M Q2 '21: 49.3M Q3 '21: 49.3M Q1 '22: 49.3M Q2 '22: 49.3M Q3 '22: 49.6M Q1 '23: 50.7M Q2 '23: 52.9M Q3 '23: 138.4M Q1 '24: 61.8M Q2 '24: 63.4M Q3 '24: 63.9M Q1 '25: 63.9M Q2 '25: 63.9M Q3 '25: 63.9M Q1 '26: 70.2M Q2 '26: 120.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 0.00 15.00 30.00 45.00 Q3 '20: 0.05 Q4 '20: 30.00 Q1 '21: 29.72 Q2 '21: 29.96 Q3 '21: 29.79 Q4 '21: -0.32 Q1 '22: -0.18 Q2 '22: -0.41 Q3 '22: -0.36 Q4 '22: -0.21 Q1 '23: -0.25 Q2 '23: -0.10 Q3 '24: -0.03 Q4 '24: -0.10 Q1 '25: -0.07 Q2 '25: -0.06 Q3 '25: -0.12 Q4 '25: -0.12 Q1 '26: -0.13 Q2 '26: -0.09 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.